首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Early increases in renal kallikrein secretion on administration of potassium or ATP-sensitive potassium channel blockers in rats
【2h】

Early increases in renal kallikrein secretion on administration of potassium or ATP-sensitive potassium channel blockers in rats

机译:在大鼠中施用钾或ATP敏感性钾通道阻滞剂后肾脏激肽释放酶分泌的早期增加

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="enumerated" style="list-style-type:decimal">This study aimed to examine whether administration of potassium or ATP-sensitive potassium channel (KATP channel) blockers caused early increases in renal kallikrein (KK) secretion. To clarify this mechanism, the effect on renal KK secretion of a KATP channel blocker was compared with the effect resulting from use of an osmotic diuretic or volume load. Furthermore, the effect on potassium-induced increases in renal KK secretion by an additional treatment using a KATP channel blocker was examined. Lastly, the effect of a KATP channel blocker on renal KK secretion was also examined in superfused slices of kidney cortex.Intravenous infusion of potassium augmented renal KK secretion within 30 min while urine volume increased gradually in both the potassium loading and control groups.Administration of the KATP channel blocker, 4-morpholinecarboximidine-N-1-adamantyl-N′-cyclohexylhydrochloride (PNU-37883A) or glibenclamide, caused a dose-dependent increase in renal KK secretion.The concentration of KK in urine was higher in the PNU-37883A group as compared to the osmotic-diuretic or volume-load group.PNU-37883A had no additive effect on the potassium-induced increase in renal KK secretion.Renal KK secretion increased in slices of kidney cortex incubated with PNU-37883A within 10 min of superfusion.In conclusion, administration of both potassium and KATP channel blockers induced early increases in renal KK secretion in the absence of the washout phenomenon. Potassium loading may have increased renal KK secretion through the same mechanism as the KATP channel blocker.
机译:class =“ enumerated” style =“ list-style-type:decimal”> <!-list-behavior =枚举前缀-word = mark-type = decimal max-label-size = 0-> 这项研究旨在检查是否施用钾或ATP敏感性钾通道(KATP通道)阻断剂引起了肾激肽释放酶(KK)分泌的早期增加。为了阐明该机制,将KATP通道阻滞剂对肾脏KK分泌的作用与使用渗透性利尿剂或体积负荷产生的作用进行了比较。此外,还研究了使用KATP通道阻滞剂对钾引起的肾KK分泌增加的影响。最后,还在肾皮质的融合切片中检查了KATP通道阻滞剂对肾脏KK分泌的影响。 静脉输注钾可在30分钟内增强肾脏KK分泌,而尿液中的钾均逐渐增加负荷和对照组。 服用KATP通道阻滞剂,4-吗啉羧酰亚胺-N-1-金刚烷基-N'-环己基盐酸盐(PNU-37883A)或格列本脲会导致肾KK剂量依赖性增加。 PNU-37883A组的尿液中KK的浓度高于渗透性利尿或体积负荷组。 PNU-37883A没有累加作用钾可引起肾脏的KK分泌增加。 在灌注10分钟内,与PNU-37883A一起孵育的肾皮质切片中的肾KK分泌增加。 最后,给药缺钾和钾离子通道阻滞剂均可诱导肾KK分泌的早期增加冲刷现象。钾负荷可能通过与KATP通道阻滞剂相同的机制增加了肾脏的KK分泌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号